ARTICLE | Clinical News
Posiphen: Phase II started
February 22, 2010 8:00 AM UTC
QR Pharma began a Phase II trial to evaluate 240 mg/day oral Posiphen given for 10 days in patients with early stage AD. The company has exclusive, worldwide rights to Posiphen from TorreyPines Thera...